What changed
$VKTX — SELL 📊
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
🎯 Q1 FY26 | EPS $-1.37 vs $-0.91 🔴
💡 Consensus expects VK2735 to dominate the obesity market rapidly, justifying $100B. My variant view: the market underestimates competition (LLY, NVO, Structure Therapeutics), overestimates efficacy and speed, and fails to discount clinical/regulatory risks.
📉 Reward/Risk: 2.74:1
🏢 Business Quality: 5/10 - Strong pipeline targetting obesity, but no approved products, zero revenue, high cash burn, and unproven commercialization.
📊 Valuation: rich — Market cap $100B vs. zero revenue. EV/Sales n/a. P/E negative. Comparable pre-revenue obesity biotechs (Altimmune, Structure) trade at $1-5B.
📊 Our read: SELL. Full analysis →
https://stockduty.xyz/s/VKTX0617
Why it matters
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.